July 23 | 2019
2cureX meddelar att patienter framgångsrikt inkluderats i pankreascancerstudie med IndiTreat®
Read more
June 27 | 2019
Last day of trading in BTA 1 in 2cureX AB
Read more
June 27 | 2019
Sista dag för handel med BTA 1 i 2cureX AB
Read more
June 25 | 2019
Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB
Read more
June 25 | 2019
Byte av Certified Adviser till Svensk Kapitalmarknadsgranskning AB
Read more
June 20 | 2019
2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer
Read more
June 20 | 2019
2cureX utser Dr. Henrik Harling till Chief Medical Officer
Read more
May 28 | 2019
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2019
Kommuniké från årsstämma i 2cureX AB (publ)
Read more
May 28 | 2019
Kraftigt övertecknad företrädesemission i 2cureX AB
Read more
May 28 | 2019
Significantly oversubscribed rights issue in 2cureX AB
Read more
May 10 | 2019
2cureX invites to an investor meeting in Stockholm on May 15th, 2019
Read more
May 10 | 2019
2cureX inbjuder till investerarträff i Stockholm den 15 maj 2019
Read more
May 9 | 2019
CORRECTION: 2cureX publishes interim report for the first quarter of 2019
Read more
May 9 | 2019
Today, the subscription period starts in 2cureX’s rights issue
Read more
May 9 | 2019
Idag inleds teckningstiden i 2cureX företrädesemission
Read more
May 8 | 2019
2cureX publishes memorandum ahead of the rights issue
Read more
May 8 | 2019
2cureX offentliggör memorandum inför företrädesemissionen
Read more